Pentavalent vaccine

Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines

Retrieved on: 
Sunday, September 11, 2022
Medical school, Congo, Virus, World, Emergency, Certification, Laboratory, EUL, Ministry of Law and Human Rights, COVAX, Communication, EUA, Food, UNICEF, Child, BMGF, Directorate, Pentavalent vaccine, Bio, DGIP, Ageing, Bill & Melinda Gates Foundation, Patent, COVID-19, Faculty, Hearing, Ministry of Law, Udayana University, Emergency Use Authorization, Vaccine, Public health, WHO, Oral polio vaccine AIDS hypothesis, Baylor College of Medicine, Intellectual property, World Health Organization, Democratic republic, Bio Farma, Representative, House, PATH, Documentation, Pharmaceutical industry, Medicine, Radical honesty

After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.

Key Points: 
  • After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.
  • All Covid-19 vaccines made by Bio Farma, including the primary series vaccines, booster vaccines and vaccines for children, will be labelled IndoVac.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like Bill and Melinda Gates Foundation (BMGF), PATH and the WHO.
  • Bio Farma has since become the main supplier of polio vaccines in the world, and currently contributes 67 percent to the global supply of polio vaccines.

Global Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024: Assessment, Future Trends, Unmet Needs, Marketed Vaccines

Retrieved on: 
Monday, March 15, 2021
Vaccines, Medical specialties, Health care, Health, Vaccine, Pentavalent vaccine, Meningococcal vaccine, Pfizer

DUBLIN, March 15, 2021 /PRNewswire/ -- The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 15, 2021 /PRNewswire/ -- The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of GlaxoSmithKline's and Pfizer's pentavalent vaccines in H2 2023 and H1 2024, respectively.
  • The five major European markets (France, Germany, Italy, Spain, and the UK) are expected to experience anemic growth over the forecast period because pentavalent vaccines have much lesser appeal within the EU.
  • Thus, with compelling immunogenicity data in both of the key market segments for MenACWY vaccines, MenQuadfi is expected to erode the market shares of both incumbents.

Global Meningococcal Vaccines Disease Forecast and Market Analysis Report 2021-2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Health, General Health, Vaccines, Medical specialties, Health care, Medicine, Vaccination, Hepatitis B, Diphtheria, Pentavalent vaccine, Tetanus, Meningococcal vaccine, Vaccine, Pfizer

The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The five major European markets (France, Germany, Italy, Spain, and the UK) are expected to experience anemic growth over the forecast period because pentavalent vaccines have much lesser appeal within the EU.
  • Thus, with compelling immunogenicity data in both of the key market segments for MenACWY vaccines, MenQuadfi is expected to erode the market shares of both incumbents.
  • GlaxoSmithKline and Pfizer are both developing pentavalent vaccines, MenABCWY and PF-06886992, respectively, which aim to partially or completely replace separate MenACWY and MenB vaccines for adolescents in the lucrative US market.

Intravacc's Sabin Inactivated Polio vaccine (sIPV), out-licensed to LG Chem, receives WHO prequalification

Retrieved on: 
Thursday, January 21, 2021
Medical specialties, Medicine, Vaccination, Vaccines, Virology, Polio vaccine, Polio eradication, Vaccine, Polio, Pentavalent vaccine, Attenuated vaccine

The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.

Key Points: 
  • The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.
  • The company will supply the vaccine to 70 countries in the Middle East, Africa and Southeast Asia starting in January 2021.
  • Intravacc will receive milestones and low single digit royalties for its considerable role in the development of this vaccine.
  • To reduce the use of the virulent vaccine derived polioviruses, a switch to inactivated polio vaccines (IPV) was desired.

Intravacc's Sabin Inactivated Polio vaccine (sIPV), out-licensed to LG Chem, receives WHO prequalification

Retrieved on: 
Thursday, January 21, 2021
Medical specialties, Medicine, Vaccination, Vaccines, Virology, Polio vaccine, Polio eradication, Vaccine, Polio, Pentavalent vaccine, Attenuated vaccine

The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.

Key Points: 
  • The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.
  • The company will supply the vaccine to 70 countries in the Middle East, Africa and Southeast Asia starting in January 2021.
  • Intravacc will receive milestones and low single digit royalties for its considerable role in the development of this vaccine.
  • To reduce the use of the virulent vaccine derived polioviruses, a switch to inactivated polio vaccines (IPV) was desired.

Sanofi's pediatric vaccine "Hexaxim" remains the most administered hexavalent vaccine in the world with 62% of volume share

Retrieved on: 
Monday, November 23, 2020
Medical specialties, Vaccines, Whooping cough, Diphtheria, Tetanus, Clinical medicine, Medicine, Polio, DPT vaccine, Hexavalent vaccine, Vaccine, Pentavalent vaccine

NEW YORK, Nov. 23, 2020 /PRNewswire/ -- A new study on the usage patterns of pediatric hexavalent vaccines reveals that Sanofi's vaccine "Hexaxim" remains the most administered hexavalent vaccine in the world in 2019 with 62% of volume share, followed by Infanrix Hexa (32%,) and Vaxelis 6%.

Key Points: 
  • NEW YORK, Nov. 23, 2020 /PRNewswire/ -- A new study on the usage patterns of pediatric hexavalent vaccines reveals that Sanofi's vaccine "Hexaxim" remains the most administered hexavalent vaccine in the world in 2019 with 62% of volume share, followed by Infanrix Hexa (32%,) and Vaxelis 6%.
  • Hexavalent vaccines are six in-one combination vaccines that protect babies against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, haemophilus influenza type B and hepatitis B.
  • In 2019, the top 35 countries consumed 22 million doses of hexavalent vaccines which represents 92% of the hexavalent vaccine global consumption.
  • Overall, Europe accounts for 42% of the hexavalent vaccines market by volume.

Global Meningococcal Vaccines Disease Coverage Report 2020-2024 - Improvements in Meningococcal Vaccination Coverage Rates in At-Risk Populations

Retrieved on: 
Tuesday, November 10, 2020
Vaccines, Medical specialties, Health care, Health, Vaccination, Meningococcal vaccine, Sanofi, Vaccine, Pfizer, Pentavalent vaccine

DUBLIN, Nov. 10, 2020 /PRNewswire/ -- The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 10, 2020 /PRNewswire/ -- The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of GlaxoSmithKline's and Pfizer's pentavalent vaccines in H2 2023/H1 2024.
  • There is very limited activity in the meningococcal vaccines pipeline, with only three candidates in clinical-stage development.
  • Antibacterial, mycobacterial, or fungal assets take 9.6 years on average from Phase I to approval, slightly longer than the 9.1 years in the overall infectious disease space.

Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 3, 2020
Health, Pharmaceutical, Bacteria, Vaccines, Medical specialties, Microbiology, Meningococcal vaccine, Vaccine, Pentavalent vaccine, Neisseria meningitidis, Pfizer

The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of GlaxoSmithKline's and Pfizer's pentavalent vaccines in H2 2023/H1 2024.
  • Beyond this period, market growth will be driven by the uptake of pentavalent vaccines, which could significantly boost coverage for the MenB component by linking the higher coverage rates observed with the booster dose of MenACWY in adolescents (53.7% in 2019) to the suboptimal coverage rates with MenB vaccines (21.8% of 17-year-olds received at least one MenB dose in 2019).
  • Antibacterial, mycobacterial, or fungal assets take 9.6 years on average from Phase I to approval, slightly longer than the 9.1 years in the overall infectious disease space.

SutroVax Announces Name Change to Vaxcyte

Retrieved on: 
Thursday, May 21, 2020
Vaccines, Vaccination, Medical specialties, Virology, Medicine, Vaccine, Health, Conjugate vaccine, Pneumococcal conjugate vaccine, Vaccination schedule, Pentavalent vaccine, Cell-based vaccine

FOSTER CITY, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc.

Key Points: 
  • FOSTER CITY, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc.
  • We are committed to developing superior vaccines that provide broader protection than what is available currently and to developing novel vaccines that target pathogens for which no approved vaccines exist, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • As an example, Vaxcyte has leveraged this platform and know-how, utilizing site-specific conjugation, to develop its lead pneumococcal conjugate vaccine program to incite T-cell and B-cell-mediated (leukocyte) immune responses.
  • Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Vaccines Market Worth $58.4 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, January 29, 2020
Vaccines, Medical specialties, Vaccination, Vaccine, Virology, Medicine, Microbiology, Conjugate vaccine, RTT, Pentavalent vaccine, Indian Immunologicals Limited

By technology, the conjugate vaccines segment accounted for the largest market share in 2018.

Key Points: 
  • By technology, the conjugate vaccines segment accounted for the largest market share in 2018.
  • On the basis of technology, the Vaccines Market has been segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines.
  • The conjugate vaccines segment accounted for the largest share of the market in 2018.
  • On the basis of type, the Vaccines Market has been segmented into monovalent and multivalent vaccines.